Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 1 2Phase NA 1

Status

Active not recruiting 2Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Plasma cell 1Gynecologic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Triple Negative Breast Neoplasms 1Prostatic Neoplasms 1Ovarian Neoplasms 1Multiple Myeloma 1Colorectal Neoplasms 1

Interventions

pembrolizumab 1254Specimen Handling 869Carboplatin 818Magnetic Resonance Spectroscopy 804Cyclophosphamide 795Cisplatin 716Nivolumab 648Paclitaxel 623Radiotherapy 567Gemcitabine 565Biopsy 529Bevacizumab 468Dexamethasone 434fludarabine 404Docetaxel 373venetoclax 366Oxaliplatin 362Capecitabine 353Fluorouracil 352atezolizumab 341Rituximab 327durvalumab 326Doxorubicin 313Radiosurgery 306Pemetrexed 303Drug Therapy 295Standard of Care 292Ipilimumab 290Etoposide 280Radiation 278

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Interventional × Maximum Tolerated Dose × 1 year × Clear all
NCT05976555 2026-05-20

Phase I Trial of BCMA-TGF-BETA CAR-T Cells in Relapsed, Refractory Myeloma

Medical College of Wisconsin

Phase 1 Not yet recruiting
30 enrolled
Plasma cell

Multiple Myeloma

NCT03663218 2026-03-18

PREPARE SBRT

Weill Medical College of Cornell University

Phase NA Active not recruiting
16 enrolled 9 charts
Genitourinary

Prostatic Neoplasms

NCT05212012 2025-10-03

MEFOX

AIO-Studien-gGmbH

Phase 1/2 Active not recruiting
11 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT03838367 2025-09-09

Leronlimab (PRO 140) Combined With Carboplatin in Patients With Cytokine Chemokine Receptor 5 Positive (CCR5+) mTNBC

CytoDyn, Inc.

Phase 1/2 Terminated
10 enrolled 15 charts
Breast

Triple Negative Breast Neoplasms

NCT06976892 2025-08-13

IDOL

Institute of Cancer Research, United Kingdom

Phase 1 Recruiting
33 enrolled
Gynecologic

Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡